128 related articles for article (PubMed ID: 12440407)
1. Pneumonia vaccine protocol could save money and lives.
Levenson D
Rep Med Guidel Outcomes Res; 2002 Mar; 13(5):5-7. PubMed ID: 12440407
[No Abstract] [Full Text] [Related]
2. Do your part to stave off STREP.
Schweon SJ
RN; 2005 Oct; 68(10):34-8; quiz 39. PubMed ID: 16259184
[No Abstract] [Full Text] [Related]
3. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
6. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
Davis MM
Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
8. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
9. Progress in vaccines, progress in health economics.
Annemans L
Vaccine; 2010 Nov; 28 Suppl 6():G1-2. PubMed ID: 21075264
[No Abstract] [Full Text] [Related]
10. Implementation and evaluation of a nursing assessment/standing orders-based inpatient pneumococcal vaccination program.
Eckrode C; Church N; English WJ
Am J Infect Control; 2007 Oct; 35(8):508-15. PubMed ID: 17936141
[TBL] [Abstract][Full Text] [Related]
11. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
[TBL] [Abstract][Full Text] [Related]
12. Vaccinating against influenza and pneumococcus.
Umeed M
Nurs Times; 2001 Oct 18-24; 97(42):32-4. PubMed ID: 11966119
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
15. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
17. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
Whitney CG
Geriatrics; 2003 Oct; 58(10):20-2, 25. PubMed ID: 14569639
[TBL] [Abstract][Full Text] [Related]
18. The role of television advertising in increasing pneumococcal vaccination coverage among the elderly, North Coast, New South Wales, 2006.
Wallace C; Corben P; Turahui J; Gilmour R
Aust N Z J Public Health; 2008 Oct; 32(5):467-70. PubMed ID: 18959552
[TBL] [Abstract][Full Text] [Related]
19. Declining invasive pneumococcal disease in the U.S. elderly.
McBean AM; Park YT; Caldwell D; Yu X
Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788
[TBL] [Abstract][Full Text] [Related]
20. Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma--United States, 2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2004 Nov; 53(43):1007-12. PubMed ID: 15525897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
